Hypothyroidism

NICE CKS Hypothyroidism. Last revised: Nov 2024. NICE guideline [NG145] Thyroid disease: assessment and management. Last updated: Oct 2023.

Background Information

There are 3 main types of hypothyroidism:
 
Type Free T4 TSH
Primary overt hypothyroidism
Secondary overt hypothyroidism
Subclinical hypothyroidism Normal

Myxoedema coma is a rare, life-threatening medical emergency due to untreated severe hypothyroidism with multi-organ failure

 

Do not mix myxoedema coma up with the following terms:

  • Myxoedema: generalised thickening and swelling of the skin and subcutaneous tissue due to the accumulation of mucopolysaccharides in the dermis. This is caused by long-standing hypothyroidism
  • Pretibial myxoedema: localised dermopathy over the shins in Graves' disease (autoimmune-induced overproduction of glycosaminoglycans)

Causes can be grossly categorised into primary and secondary hypothyroidism.
 

  • Iron deficiency - most common worldwide cause
  • Autoimmune thyroiditis - most common cause in the UK (and other iodine-sufficient areas)
    • Hashimoto's thyroiditis
    • Atrophic thyroiditis
  • Transient thyroiditis
    • De Quervain's (subacute) thyroiditis
    • Postpartum thyroiditis
  • Iatrogenic (e.g. from surgery, radioiodine therapy, radiotherapy, anti-thyroid drugs)
  • Congenital hypothyroidism (most common due to thyroid gland dysgenesis)
  • Infiltrative disorders (e.g. amyloidosis, sarcoidosis, tuberculosis, malignant infiltration)

Essentially any cause of pituitary or hypothalamic dysfunction

Diagnosis Guidelines

NICE recommends testing for thyroid dysfunction in:
  • Clinically suspected cases
  • Type 1 diabetes or other autoimmune disease
  • New-onset atrial fibrillation

Choice of test:
  • Primary hypothyroidism suspected → TSH alone, and only measure free T4 if TSH is abnormal
  • Secondary hypothyroidism suspected → TSH and free T4 at the start
 

Type Free T4 TSH
Primary overt hypothyroidism
Secondary overt hypothyroidism
Subclinical hypothyroidism Normal
 

Standard additional tests:
  • Anti-TPOThyroid peroxidase antibodies (consider in both primary overhypothyroidism and subclinical hypothyroidism)
  • FBC and serum B12 levels (to screen for prenicious anaemia)
  • HbA1c (to screen for type 1 diabetes)
  • Coeliac serology (to screen for coeliac disease)
  • Serum lipids (to assess for associated dyslipidaemia)

If there is palpable thyroid enlargement or focal nodularity → ultrasound neck

Summary Table

Condition Antibody serology Ultrasound findings Technetium / radioiodine uptake scan
Graves’ disease
  • Anti-TSH receptor antibodies +ve in >90%
  • Anti-TPO can be +ve
  • Diffuse enlargement
  • ↑ Vascularity 
  • ↑ Doppler
  • Diffuse ↑ uptake
Toxic multinodular goitre
  • -ve
  • Multiple nodules of varying size
  • Heterogeneous echotexture
  • Multifocal (patchy) ↑ uptake
Toxic adenoma
  • -ve
  • Solitary, well-defined nodule
  • Focal ↑ uptake (hot nodule)
  • ↓ Uptake of remaining areas
Hashimoto’s thyroiditis
  • Anti-TPO +ve in >90%
  • Diffuse enlargement
  • Heterogeneous hypoechoic echotexture
  • Diffuse ↓ uptake
Subacute (De Quervain’s) thyroiditis
  • -ve
  • Diffuse enlargement
  • Hypoechoic areas
  • ↓ Vascularity
  • Diffuse ↓ uptake
Thyroid cancer
  • -ve
  • Solid hypoechoic nodule +/- microcalcifications
  • Focal ↓ uptake

Management Guidelines

Offer levothyroxine


Recommended doses:
  • ≥65 y/o with history of cardiovascular disease: start with 25-50 mcg per day
  • Other patients: 1.6 mcg/kg (rounded to nearest 25 mcg)
    • = 125 mcg per day for a 70kg adult

 

Patient should be advised to take levothyroxine first thing in the morning on an empty stomach before other food or medications.

Note that transient thyroiditis (i.e. De Quervain's and postpartum thyroiditis) do not require routine levothyroxine therapy as they are usually self-limited.

Aim to maintain TSH within the reference range, measure TSH (adults):
  • Initially, every 3 months until stabilised (2 similar consecutive measurements)
  • Then, annually

Do not routinely offer levothyroxine in subclinical hypothyroidism.

Consider levothyroxine therapy in:
  • TSH ≥10 on 2 separate occasions, 3 months apart, or
  • Symptomatic (and elevated TSH on 2 separate occasions, 3 months apart)

Author: Adams Lau
Reviewer:
Last edited: 15/08/25